Key statistics
On Tuesday, Monopar Therapeutics Inc (MNPR:NAQ) closed at 5.34, -38.27% below its 52-week high of 8.65, set on Feb 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.19 |
---|---|
High | 5.66 |
Low | 5.09 |
Bid | 5.21 |
Offer | 5.59 |
Previous close | 5.08 |
Average volume | 612.80k |
---|---|
Shares outstanding | 3.52m |
Free float | 1.64m |
P/E (TTM) | -- |
Market cap | 18.80m USD |
EPS (TTM) | -2.31 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Announcements
- Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
- Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
- Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
- Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
- Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
- Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
- Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
- Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
- Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
More ▼